The screening of antiviral activity of compounds can be done by several methods, some of which are low-throughput, such as the plaque reduction method, which is a time-consuming, laborious, and subjective measurement. On the other hand, some of the reported screening methods for anti-infection compounds are quantitative and high-throughput, but they often use new technologies, such as expensive equipment and software, which limit their use. To bypass these problems, we can use cell-based ELISA (also called in situ ELISA) to screen antiviral drugs for influenza A virus, varicella-zoster virus, dengue virus, human cytomegalovirus, etc. Compared with the untreated control, the abundance of viral proteins in infected cells treated with the test article was used to measure antiviral activity. Cell-based ELISA is suitable for automation, using materials and reagents commonly used in many laboratories, providing objective and fast results. The analysis is standardized and validated.